TY - JOUR T1 - Single-cell spatial analysis of tumor immune architecture in diffuse large B cell lymphoma JF - medRxiv DO - 10.1101/2021.02.01.21250775 SP - 2021.02.01.21250775 AU - Anthony Colombo AU - Monirath Hav AU - Erik Gerdtsson AU - Mohan Singh AU - Alexander Xu AU - Alicia Gamboa AU - Denaly Chen AU - Jane Houldsworth AU - Rita Shaknovich AU - Tomohiro Aoki AU - Lauren Chong AU - Katsuyoshi Takata AU - Elizabeth A Chavez AU - Christian Steidl AU - James Hicks AU - Peter Kuhn AU - Imran Siddiqi AU - Akil Merchant Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/03/2021.02.01.21250775.abstract N2 - Multiplexed immune cell profiling of the tumor microenvironment (TME) in cancer has improved our understanding of cancer immunology, but complex spatial analyses of tumor-immune interactions in lymphoma are lacking. Here we used imaging mass cytometry (IMC) on 33 cases of diffuse large B cell lymphoma (DLBCL) to characterize tumor and immune cell architecture and correlate it to clinicopathological features such as cell of origin, gene mutations, and responsiveness to chemotherapy. To understand the poor response of DLBCL to immune check point inhibitors (ICI), we compared our results to IMC data from Hodgkin lymphoma (HL), a cancer highly responsive to ICI, and observed differences in the expression of PD-L1, PD-1, and TIM-3. We created a spatial classification of tumor cells and identified sub-regions of immune activation, immune suppression, and immune exclusion within the topology of DLBCL. Finally, the spatial analysis allowed us to identify markers such as CXCR3, which are associated with penetration of immune cells into immune desert regions, with important implications for engineered cellular therapies.SIGNIFICANCE This is the first study to integrate tumor mutational profiling, cell of origin classification, and multiplexed immuno-phenotyping of the TME into a spatial analysis of DLBCL at the single cell level. We demonstrate that, far from being histo-pathologically monotonous, DLBCL has a complex tumor architecture, and that changes in tumor topology can be correlated with clinically relevant features. This analysis identifies candidate biomarkers and therapeutic targets such as TIM-3, CCR4, and CXCR3 that are relevant for combination treatment strategies in immuno-oncology and cellular therapies such as CAR-T cells.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by funding from the Ming Hsieh Institute at University of Southern California to A.M., J.H. and P.K. Additional support for this project was provided by K08 CA154975-01A1 career development award to A.M. from the National Cancer Institute, and a Paul Allen Distinguished Investigator award (Frontiers Group; C. Steidl). Access to the imaging mass cytometry system was obtained through the Fluidigm Early Access Program and support from the USC Michelson CSI-Cancer program. The content is solely the responsibility of the authors and does not necessarily 35 represent the official views of the National Cancer Institute or the National Institute of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with the Declaration of Helsinki. Protocols for tissue and clinical data collection were approved by the USC Health Sciences Institutional Review Board. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata is public available, and can be used/shared https://github.com/arcolombo/singleCell_DLBCL ER -